Zevra Therapeutics Faces Setback as EMA Panel Rejects Arimoclomol for NPC
Event summary
- The CHMP of the EMA issued a negative opinion on Zevra's MAA for arimoclomol to treat Niemann-Pick disease type C (NPC) in the EU.
- Zevra plans to request a re-examination of the CHMP opinion, citing confidence in the evidence supporting arimoclomol.
- The company continues to provide access to arimoclomol through its global Expanded Access Program (EAP).
- Updated international consensus guidelines endorse arimoclomol as an important treatment option for NPC.
The big picture
Zevra's setback with the CHMP highlights the challenges of securing regulatory approval for rare disease treatments, even when backed by consensus guidelines. The company’s decision to seek re-examination underscores the high stakes in bringing arimoclomol to market, as NPC patients face significant unmet medical needs. Success or failure here could influence broader strategies for orphan drug approvals in the EU.
What we're watching
- Regulatory Strategy
- Whether Zevra's request for re-examination will succeed in overturning the CHMP's negative opinion.
- Clinical Evidence
- The pace at which real-world evidence from the EAP could bolster arimoclomol’s case for approval.
- Market Access
- How the negative opinion may impact patient access and commercialization plans in Europe.